ArticleBMC ophthalmology2022
Plasma and aqueous levels of alarin and adipsin ın patients with and without diabetic retinopathy.
Article in BMC ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- Serum levels of GDF-15, betatrophin, TNF-α and IL-6 in diabetic patients with and without diabetic complications.Saudi medical journal · 2025Article
- Serum levels of galanin-like peptide and alarin are highly correlated with polycystic ovary syndrome.Scientific reports · 2025Article
- Aqueous humor adipokine profile of primary open angle glaucoma patients and cataract patients with or without metabolic disorders.International journal of ophthalmology · 2025Article
- [Neuroendocrine features of the pathogenesis of polycystic ovary syndrome (literature review)].Problemy endokrinologii · 2023Article
- Exploring the Potential Link between Acute Central Serous Chorioretinopathy and Trimethylamine N-Oxide, Phoenixin, Spexin, and Alarin Molecules.Biomolecules · 2023Article
- Plasma and aqueous levels of subfatin, preptin and betatrophin in patients with diabetic retinopathy.BMC ophthalmology · 2023Article
- Regulatory effects and potential therapeutic implications of alarin in depression, and arguments on its receptor.Frontiers in psychiatry · 2022Review
- The evolving roles of alarin in physiological and disease conditions, and its future potential clinical implications.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backroundDiabetic retinopathy is a disease seen with microvascular complications as a result of hyperglycemia and insulin resistance. Alarin and Adipsin are molecules with a role in energy and glucose metabolism. The aim of this study was to determine plasma and aqueous levels of Alarin and Adipsin in patients with and without diabetic retinopathy to evaluate their potential roles in diabetic retinopathy.
methodsThe study included one eye from each of 20 cataract patients without diabetes (C), 20 cataract patients with diabetes and without diabetic retinopathy (DM + C), and 20 cataract patients with diabetes and diabetic retinopathy (DR + C). Plasma and aqueous humour samples were taken from all patients during the cataract operation. Alarin and Adipsin levels were examined with the enzyme-linked immunosorbent assay (ELISA) method.
resultsBoth plasma and aqueous Alarin levels were significantly higher in the patients with diabetic retinopathy than in the control group (p < 0.001, p = 0.006). Adipsin levels were found to be significantly higher in plasma in the control group than in the DR + C group and significantly higher in aqueous in the DR + C group than in the control group (p < 0.001, p < 0.001).
conclusionThese findings suggest that Alarin and Adipsin may play important role in diabetic retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.